Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Dec 16, 2024
- Pharmaceuticals
- R&D
Galderma’s Announcement Regarding NEMLUVIO (FDA Approval for the Treatment of Moderate to Severe Atopic Dermatitis)
TOKYO, December 16, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Galderma issued a press release on December 14 that the U.S. Food and Drug Administration (FDA) has approved the humanized anti-human IL-31 receptor A monoclonal antibody NEMLUVIO® (nemolizumab) for the treatment of moderate to severe atopic dermatitis. NEMLUVIO was created by Chugai, and its clinical development outside Japan is being conducted by Galderma.
Please refer to the link below for details of the Galderma’s press release:
Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis
https://www.galderma.com/news/galderma-receives-us-fda-approval-nemluvior-nemolizumab-patients-moderate-severe-atopic
Trademarks used or mentioned in this release are protected by laws.
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp